
In the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...
Read moreVisit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...
Read moreWe would like to invite you to the 23rd Kapras Day on the topic of "Clinical Genetics," which will take place on Wednesday, February 26, 2025, in the Congress Hall of Hotel Olšanka in Prague. We loo...
Read moreThe JAK family of non-receptor tyrosine kinases, includes JAK1, JAK2, JAK3, and TYK2. Growth factors and cytokines can regulate gene transcription through JAK-dependent activation of signal transducer and activator of transcription (STAT). The JAK-STAT signal transduction pathway regulates cell proliferation, differentiation, apoptosis and immune regulation. Activation of JAK2 by mutation of the amino acid at position 617 (V617F ) is associated with myeloproliferative disorders, including polycythemia vera (mutations found in 90% of cases), essential thrombocythemia (50%) and idiopathic myelofibrosis (50%). JAK2 mutation is the main diagnostic indicator of MPD. The ADx JAK2 V617F Mutation Detection Kit is a highly selective and sensitive assay for detecting the V617F mutation in the JAK2 oncogene. AmoyDx’s patented technology allows detection of 1% mutant DNA in a background of 99% normal DNA, while ensuring that false negatives are minimized. The procedure is easilyadapted for use in high-throughput sample processing.